Search

Your search keyword '"Laforet, Pascal"' showing total 357 results

Search Constraints

Start Over You searched for: Author "Laforet, Pascal" Remove constraint Author: "Laforet, Pascal"
357 results on '"Laforet, Pascal"'

Search Results

2. Analysis of muscle magnetic resonance imaging of a large cohort of patient with VCP-mediated disease reveals characteristic features useful for diagnosis

3. Correction to: Analysis of muscle magnetic resonance imaging of a large cohort of patient with VCP‑mediated disease reveals characteristic features useful for diagnosis

4. Genotype-phenotype correlations in valosin-containing protein disease: a retrospective muticentre study.

6. Hypersensitivity infusion-associated reactions induced by enzyme replacement therapy in a cohort of patients with late-onset Pompe disease: An experience from the French Pompe Registry

8. Cardiac Outcomes in Adults With Mitochondrial Diseases

11. Clinical practice guidelines for glycogen storage disease V & VII (McArdle disease and Tarui disease) from an international study group

12. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial

13. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial

14. A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease

15. A Caribbean case of phosphoglycerate mutase deficiency: Relevance of forearm exercise test and electroneuromyography with long exercise test in the diagnosis strategy of rare muscle glycogenosis

16. Home-based exercise in autoimmune myasthenia gravis: A randomized controlled trial

17. Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial

18. Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid α-Glucosidase in Pompe Patients Co-administered with Alglucosidase α

19. Start, switch and stop (triple‐S) criteria for enzyme replacement therapy of late‐onset Pompe disease: European Pompe Consortium recommendation update 2024.

21. European muscle MRI study in limb girdle muscular dystrophy type R1/2A (LGMDR1/LGMD2A)

23. Prognosis of Right Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy

28. Identifying Digital Biomarkers for the Self-Monitoring of Patients Living with Generalized Myasthenia gravis: a Proof of Concept (P7-8.007)

32. FSHD1 and FSHD2 form a disease continuum

35. Dermatomyositis With or Without Anti-Melanoma Differentiation-Associated Gene 5 Antibodies: Common Interferon Signature but Distinct NOS2 Expression

37. Clinical heterogeneity and phenotype/genotype findings in 5 families with GYG1 deficiency

38. Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase

40. Affected female carriers of MTM1 mutations display a wide spectrum of clinical and pathological involvement: delineating diagnostic clues

41. Proceedings of Réanimation 2017, the French Intensive Care Society International Congress

43. Genotype-phenotype correlations in valosin-containing protein disease

48. Unravelling the impact of frontal lobe impairment for social dysfunction in myotonic dystrophy type 1

49. Muscle MRI findings in limb girdle muscular dystrophy type 2L

Catalog

Books, media, physical & digital resources